Russian pharmaceutical companies eyeing expanding in the UAE

22 November 2023
russia_flag_sky_big

Russian pharmaceutical companies are eyeing expanding in the United Arab Emirates (UAE) by launching production of their drugs and establishing their manufacturing facilities in the local market, according to recent statements, by Russia’s Ministry of Industry and Trade Denis Manturov, The Pharma Letter’s local correspondent reports.

According to him, as part of the plans is producing of bioengineered drugs. In addition, particular attention will be given to the area of nosology and monoclonal antibodies as well as some other areas where Russia has the necessary competencies.

Currently the Russian government, together with some of the country’s leading drugmakers, is finishing forming the list of Russian pharmaceutical companies, which may establish their production facilities within the territory of the UAE. That list will be also a subject to approval of the UAE’s Ministry of Economy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biosimilars